GSK– Egypt sees lower profit in Q1

GlaxoSmithKline's (GSK – Egypt) (BIOC) standalone net profit fell 30% Year on Year (YoY) during the first quarter

  
Traders work at the Egyptian stock exchange in Cairo, Egypt April 18, 2016.

Traders work at the Egyptian stock exchange in Cairo, Egypt April 18, 2016.

REUTERS/Mohamed Abd El Ghany

ArabFinance: GlaxoSmithKline's (GSK – Egypt)(BIOC) standalone net profit fell 30% Year on Year (YoY) during the first quarter (Q1) of 2021, according to the company’s filing to the Egyptian Exchange.

Standalone net profit recorded EGP 22.21 million in Q1 2021, compared to EGP 31.9 million in Q1 2021.

In 2020, the company’s consolidated net profit reached EGP 28.13 million, compared to a net profit of EGP 142.6 million in 2019.

GSK Egypt, a member of the British pharmaceutical company Glaxo Group, is an Egypt-based company engaged in the manufacture, packaging, marketing, sale, and distribution of pharmaceutical products.

Copyright © 2021 Arab Finance Brokerage Company All rights reserved. Provided by SyndiGate Media Inc. (Syndigate.info).

Disclaimer: The content of this article is syndicated or provided to this website from an external third party provider. We are not responsible for, and do not control, such external websites, entities, applications or media publishers. The body of the text is provided on an “as is” and “as available” basis and has not been edited in any way. Neither we nor our affiliates guarantee the accuracy of or endorse the views or opinions expressed in this article. Read our full disclaimer policy here.

More From Equities